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HPLC–DADAbstract The present work describes development and validation of a high-performance liquid
chromatography–diode array detection (HPLC–DAD) procedure for the analysis of phenylephrine
hydrochloride (PHE), paracetamol (PAR), caffeine anhydrous (CAF), cetirizine Dihydrochloride
(CET), nimesulide (NIM) in pharmaceutical mixture. Effective chromatographic separation of
PHE, PAR, CAF, CET and NIM was achieved using a Kinetex-C18 (4.6 mm, 150 mm, 5 mm) col-
umn with gradient elution of the mobile phase composed of 10 mM phosphate buffer (pH 3.3) and
acetonitrile. The elution was a three step gradient elution program step-1 started initially with 2%
(by volume) acetonitrile and 98% phosphate buffer (pH 3.3) for ﬁrst 2 min. In step-2 acetonitrile
concentration changed linearly to 20% up to 12 min the analysis was concluded by step-3 changing
acetonitrile to 2% up to 20 min. The proposed HPLC method was statistically validated with
respect to linearity, ranges, precision, accuracy, selectivity and robustness. Calibration curves were
linear in the ranges of 5–100, 100–1000 and 10–200 mg/mL for PHE, PAR, CAF, CET and NIM
Paracetam
Phenyleph
Hydrochlo
Caffeine (
Cetirizine
Dihydroch
Nimesulid
Figure 1 The structures of Paraceta
(NIM).
592 A.P. Dewani et al.respectively, with correlation coefﬁcients >0.9996. The HPLC method was applied to tablet dosage
form in which the analytes were successfully quantiﬁed with good recovery values with no interfer-
ing peaks from the excipients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Phenylephrine (PHE) chemically is (1R)-1-(3hydroxy-phenyl)-
2-(methylamino) ethanol hydrochloride and is used as sympat-
homimetic (descongestants). Paracetamol (PAR) is analgesic
and antipyretic chemically it is N-(4-hydroxyphenyl) acetam-
ide. Caffeine (CAF) chemically is (1,3,7-trimethyl-1H-purine-
2,6(3H,7H)-dione and acts as a central nervous system stimu-
lant. Cetirizine Dihydrochloride (CET) provides prompt relief
of itchy watery eyes, runny nose, sneezing, itching of the nose
or throat due to respiratory allergies chemically it is (±)-[2-[4-
[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic
acid dihydrochloride. Nimesulide (NIM) is a selective COX-2
inhibitor which provides analgesic & antipyretic effectStructural form
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mol (PAR), Phenylephrine hydrochemically it is N-(4-Nitro-2-phenoxyphenyl) methanesulfon-
amide. Structural formulas of PHE, PAR, CAF, CET and
NIM are given in Fig. 1.
The mixture of ﬁve drugs is recommended to relieve symp-
toms such as nasal and sinus congestion, allergic symptoms of
the nose or throat due to upper respiratory tract allergies and
sinus pain associated with headache. The multidrug mixture is
also used as an adjunct with antibacterials in sinusitis, tonsilli-
tis, and otitis media.
The tablet contains a variable amount of all ingredients due
to their recommended pharmacological dose; the tablet con-
tains 10 mg of phenylephrine hydrochloride, 325 mg of para-
cetamol, 25 mg caffeine, 5 mg cetirizine and 100 mg of
nimesulide. This variable amount of ingredients in such aula
CH2NHCH3 HCl.
N
CH
H3
chloride (PHE), Caffeine (CAF), Cetirizine (CET) and Nimesulide
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difﬁcult. Moreover, the active compounds have very different
polarity and, therefore chromatographic behavior. So far no
single HPLC method is reported to determine the mentioned
ingredients quantitatively in this combination.
The literature reveals a number of analytical methods pub-
lished for PHE, PAR, CAF, CET and NIM with some other
drug combinations.
Methods for paracetamol and its combinations in pharma-
ceuticals or in biological ﬂuids have been reported. Paraceta-
mol has been determined in combination with other drugs
using titrimetry (British Pharmacopoeia, 1998; Pharmacopoeia
et al., 1997), voltammetry (Saeed and Reyhaneh-Sadat, 2011),
ﬂuorimetry (Hossein and Yahya, 2011), colorimetry (Shihana
et al., 2010), UV-spectrophotometry (Ghulam et al., 2011),
quantitative thin-layer chromatography (TLC) (Atul and Af-
sar, 2008), high-performance liquid chromatography (HPLC)
(El-Kommos et al., 2012; Godse et al., 2009; Franeta et al.,
2002; Issa et al., 2012; Gopinath et al., 2007; Olmo et al.,
2005) and gas chromatography (GC) (Belal et al., 2009) in
pharmaceutical formulations.
An HPLC method for phenylepherine in combination with
Chlorpheniramine Maleate has been reported (Mukesh et al.,
2010).
Caffeine has been analyzed in combination with some other
active agents by a variety of analytical methods such as spec-
trophotometry (Kuldeep et al., 2011), HPLC (Viswanath
et al., 2011) and HPTLC (Misra et al., 2009).
Cetirizine has been reported for analytical methods such as
HPLC for estimations in formulations and plasma (Maithani
et al., 2010; Nagaralli et al., 2003), spectrophotometry (Bhatia
et al., 2008), Capillary zone electrophoresis (Azhagvuel and
Sekar, 2007) a stability indicating assay method is also
reported (Hadada et al., 2009; Khan et al., 2011). Nimesulide
the other analyte of multidrug combination has been quanti-
ﬁed by analytical methods such as HPTLC (Patravale et al.,
2001), UV spectrophotometry (Altino¨z and Dursun, 2000), dif-
ferential pulse voltammetric (Wang et al., 2006), FT-NIR spec-
troscopy (Ajayakumar et al., 2012) and HPLC (Tzanavaras
and Themelis, 2007).
To the best of our knowledge, the methods described in the
literature do not cover the analysis of ﬁve analytes PHE, PAR,
CAF, CET and NIM in a pharmaceutical mixture in the form
of tablet formulation. Therefore, the main objective of this
work was to develop a single separation method for quantify-
ing these ﬁve analytes which are present in variable concentra-
tions in tablet dosage form.
Within this context, a simple alternative methodology for
the determination of these drugs in tablets using a gradient
chromatographic mode in analysis time of 20 min was pro-
posed. After validation of the method for various parameters,
the method proved to be successful and was applied to the
analysis of commercial product containing these active
ingredients.
2. Experimental
2.1. Chemicals and reagents
Working standards of pharmaceutical grade phenylephrine
hydrochloride, paracetamol, caffeine anhydrous, cetirizinedihydrochloride and nimesulide were obtained as generous
gifts from Leben pharmaceuticals (Akola Maharashtra, India).
They were used without further puriﬁcation. Fixed dose com-
bination tablet Ness cold plus (One Ness Pharmaceuticals
Ltd) containing 10 mg phenylephrine hydrochloride, 325 mg
Paracetamol, 25 mg caffeine, 5 cetirizine and 100 mg nimesu-
lide was purchased from local market, Yavatmal, Maharash-
tra, India. All the chemicals were of HPLC grade, purchased
from Merck Chemicals, India. Water used was double distilled
and ﬁltered through 0.45 lm ﬁlter.
2.2. Instrumentation
The HPLC system consisted of waters series 600E pump qua-
ternary gradient, waters online degasser module a 996 photo-
diode array (PDA) detector, a 515 autosampler; data were ac-
quired and processed by making use of EMPOWER software
(all equipments from Waters, Milford). The chromatographic
separations were carried out on a reverse phase Kinetex-C18
column (150 · 4.5 mm i.d., particle size 5 l, core shell
technology).
2.3. Preparation of standard stock and sample solution
2.3.1. Preparation of standard stock solution
Preliminarily sample preparation was done in acetonitrile tak-
ing accurately weighed quantity of 10 mg of PHE, 325 mg of
PAR, 25 mg of CAF, 5 mg of CET and 100 mg of NIM trans-
ferred to 100 ml volumetric ﬂasks separately to give stock solu-
tions of 100 lg/ml of PHE, 3250 lg/ml of PAR, 250 lg/ml of
CAF, 50 lg/ml of CET and 1000 lg/ml of NIM.
2.3.2. Preparation of mixed standard solution
A mixed standard solution was prepared from these stock
solutions by transferring 10 mL of each of the stock solution
to a 100 mL volumetric ﬂask and diluting with acetonitrile to
get a solution of 10, 325, 25, 5 and 100 lg/ml of PHE, PAR,
CAF, CET and NIM respectively.
2.3.3. Preparation of sample solution of tablet
For preparation of sample solution of pharmaceutical mixture
twenty tablets (Ness cold plus Tab) were weighed and pow-
dered ﬁnely. Tablet powder equivalent to 10 mg of PHE,
325 mg of PAR, 25 mg of CAF, 5 mg of CET and 100 mg of
NIM was transferred to a 100 ml volumetric ﬂask and dis-
solved in acetonitrile up to the mark. The solution was ultraso-
nicated for 15 min and ﬁltered through 0.45 l membrane ﬁlter.
The solutions were further diluted to obtain resultant concen-
tration of 10 lg/ml of PHE, 325 lg/ml of PAR, 25 lg/ml of
CAF, 5 lg/ml of CET and 100 lg/ml of NIM the resultant
mixture was subjected to HPLC analysis in developed chro-
matographic conditions.
2.4. Chromatographic Conditions
Initial trials were carried by an isocratic mode of analysis using
the mixture of phosphate buffer and organic phase acetonitrile
and methanol. Looking to the variability in polarities trials
were initiated on reverse phase Kinetex C-18 column
(150 · 4.5 mm i.d., particle size 5 l) made by core shell
594 A.P. Dewani et al.technology from Phenomenex. Experiments concluded lack of
resolution of a complex mixture of ﬁve drugs using the iso-
cratic approach of analysis. The gradient mode was opted
comprising buffer and acetonitrile as organic phase. Mobile
phase composed of 10 mM phosphate buffer (pH 3.3) and ace-
tonitrile. The elution was a three step gradient elution program
with ﬂow of 1 ml/min throughout the method, step-1 started
initially with 2% (by volume) acetonitrile and 98% phosphate
buffer for 2 min, acetonitrile concentration changed linearly to
80% in next 10 min followed by ﬁnal step-3 reverting acetoni-
trile concentration back to 2% and phosphate buffer 98% in
last 8 min thus concluding the method in total run time of
20 min, a tabular representation of developed gradient pro-
gram is given in Table 1. The eluants were monitored at
230 nm. The mobile phase was ﬁltered through 0.45 l mem-
brane ﬁlter and degassed before use. The injection volume
was 20 ll and all analyses were performed at ambient temper-
ature. Figs. 2 and 3 show the chromatogram for standard mix-
ture and spectrum index plot obtained through the optimized
variables in accordance with the features described above.
3. Results and discussion
3.1. Method development and optimization of chromatographic
conditions
The development of the method was based on the experience
obtained from the HPLC method previously developed for
the analysis of mixture of analytes comprising phenylephrine,
paracetamol, caffeine and chlorpheniramine maleate (Dewani
et al., 2012) (30) by authors. Experiments previously suggest
use of C-18 stationary phases of (150 · 4.5 mm i.d., particle size
5 lm) hence for the study a reverse phase Phenomenex Kinetex-
C18 columnmade by core shell technology was utilized. For the
separation of all the ﬁve analytes in mixture the composition
and pH of mobile phase were varied. Parameters such as mobile
phase composition of buffer at different pH values were exhaus-
tively studied so as to achieve a reasonable degree of separation
of analytes. Several binary or ternary eluants were tested using
different proportions of solvent, such as acetonitrile, methanol,
water and buffer at different pH conditions. Initially isocratic
mode of separation was experimented and was found insufﬁ-
cient to resolve the mixture with good peak characters hence
gradient mode was selected so as to achieve separation of ana-
lytes with good peak characters. The optimized gradient pro-
gram was varied by changing the organic phase in programed
steps. Initially a four step gradient program gave good separa-
tion of all the ﬁve analytes with total run time of 25 min, in or-
der to reduce the total run time it was optimized further. The
ﬁnal optimized gradient program was a three step gradient pro-
gram having total run time of 20 min thus reducing the total run
time by 5 min. The mean retention time of ﬁve analytes was
PHE 1.8, PAR 9.81, CAF 11.70, CET 14.17 and NIM
16.35 min respectively. Peak identiﬁcation was done byTable 1 Description of gradient program.
Step no. Phosphate buﬀer (%) Acetonitrile (%) Time (min)
Step 1 98 2 2
Step 2 20 80 12
Step 3 98 2 20injecting individual analyte in developed chromatographic con-
ditions. A value of 1.5 for resolution implies a complete separa-
tion of any two consecutive peaks (British Pharmacopoeia,
2010). Resolution was calculated between the adjacent peaks
of PHE, PAR, CAF, CET and NIMwhich was>1.5 indicating
an adequate degree of resolution.
3.2. Method validation
3.2.1. Selectivity and linearity
Method selectivity was assessed by the peak purity test (com-
parison between analyte peak and auto threshold in the purity
plot) using diode array detector. The analyte chromatographic
peak was not found to be attributable to more than one com-
ponent indicating the method to be selective (Conference Har-
monisation (ICH), 1995).
For linearity, an external method was used for the simulta-
neous determination of ﬁve ingredients. Five concentrations
were chosen ranging from 50% to 150% of the target analyte
concentrations in formulations. So the linearity dilution concen-
trations were PHE 5–15 lg/ml, PAR 162.5–487.5 lg/ml, CAF
12.5–37.5 lg/ml, CET 2.5–7.5 lg/ml and NIM 50–150 lg/ml.
All the solutions were prepared by diluting in acetonitrile. Each
concentration of standardmixture solutions was injected in trip-
licate and the mean value of peak area was taken for the calibra-
tion curve. Calibration graph was obtained by plotting peak
area versus concentration of standard drugs. The linear regres-
sion equations for PHE, PAR, CAF, CET andNIMwere found
to be y= 1994x+ 3388, y= 51,421x+ 25,293, y= 9641x+
16,376, y= 18,743x – 30,719 and y= 39,548x+ 22,485
respectively. The regression coefﬁcient values (R2) were found
to be 0.998, 0.997, 0.996, 0.999 and 0.996 respectively indicating
an acceptable degree of linearity.
3.2.2. Speciﬁcity
The speciﬁcity of the method was accessed from the chromato-
gram where complete separation of PHE, PAR, CAF, CET
and NIM was achieved and against potential interferences in
the presence of placebo (diluents i.e., acetonitrile). The peaks
obtained were sharp and well separated at the baseline also
excipients from formulation were not interfering with assay
no interferences were detected at retention times of PHE,
PAR, CAF, CET and NIM in sample solution proving the
method to be speciﬁc. A chromatogram for placebo studies
is shown in Fig. 4.
3.2.3. Precision
The precision of an analytical method is the closeness of repli-
cate results obtained from analysis of the same homogeneous
sample. Precision is determined through the estimate of the rel-
ative standard deviation (RSD) values. Precision studies were
carried by carrying inter-day and intra-day studies. The preci-
sion studies were done by injecting the prepared standard solu-
tion at three concentration levels (50%, 80% and 150%) in
triplicate every day up to three consecutive days for inter-
day studies. Intra-day studies were done by injecting the stan-
dards at three different times on same day. %RSD values were
measured the low value of RSD (%) showed that the method is
precise within the acceptance limit of ±2%. The intra- and in-
ter-day variability or precision data are given in Table 2. The
results indicated good precision of the developed method.
Figure 4 Chromatogram showing placebo runs in developed chromatographic conditions.
Figure 2 HPLC chromatogram obtained during simultaneous separation of PHE, PAR, CAF, CET and NIM. Chromatographic
conditions: Kinetex C-18 (150 · 4.5 mm i.d., particle size 5 l) (Phenomenex); mobile phase gradient elution of three steps, phosphate
buffer 10 mM, pH adjusted to 3.3 with ortho-phosphoric acid, and acetonitrile with step 1. (98:2) v/v for 2 min. step 2. (20:80) up to
12 min. and step 3 again achieving initial concentration of 98:2 up to 20 min. ﬂow rate of 1.0 ml/min; and UV detection at 230 nm.
Figure 3 Spectrum Index plot for simultaneous HPLC estimation of PHE, PAR, CAF, CET and NIM in pharmaceutical mixture.
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The accuracy of an analytical method expresses the closeness
of agreement between the value, which is accepted reference
value, and the value found. Accuracy studies were done by
the standard addition method. Accuracy is expressed as %recovery of the standard spiked to previously analyzed test
sample of tablet. The active ingredients were spiked in previ-
ously analyzed tablet powder sample at different concentration
levels viz. 80%, 100%, and 120% each of the labeled claim and
injected in developed chromatographic conditions in triplicate.
Table 2 Precision data of intra-day and inter-day assay (n= 6).
Concentration lg/ml Measured mean concentration ±%RSD
Inter-day precision (n= 6) Intra-day precision (n= 6)
PHE
5 4.9 ± 1.2 4.95 ± 1.5
10 10.10 ± 2.2 10.15 ± 1.2
15 15.20 ± 1.2 15.10 ± 2.3
PAR
162.5 163.2 ± 1.8 164.8 ± 1.5
325 327.5 ± 1.3 328.8 ± 2.2
487.5 493 ± 1.5 492.6 ± 1.2
CAF
12.5 12.40 ± 1.3 12.60 ± 1.8
25 25.40 ± 1.7 25.20 ± 2.2
37.5 37.90 ± 1.2 37.20 ± 1.8
CET
2.5 2.4 ± 1.2 2.5 ± 1.5
5 4.80 ± 1.2 4.90 ± 1.6
7.5 7.7 ± 1.8 7.6 ± 1.4
NIM
50 50.5 ± 1.6 50.9 ± 2.3
100 102.3 ± 2.8 101.8 ± 2.2
150 152.3 ± 1.3 153.3 ± 2.1
Table 3 Recovery data for accuracy studies.
Recovery level Std. added to placebo Amount added (mg) Mean recovery (mg) ±%RSD (n= 3) Mean % Recovery
80% PHE 8 8.1 ± 1.4 101.25
PAR 260 263.6 ± 2.2 101.38
CAF 20.0 19.6 ± 2.2 98.00
CET 4.0 4.1 ± 2.6 102.5
NIM 80 82.50 ± 1.8 103.12
100% PHE 15 15.30 ± 1.5 102.00
PAR 325 328.50 ± 1.8 101.07
CAF 25 24.8 ± 1.4 99.22
CET 5 5.15 ± 1.9 103.00
NIM 100 98.3 ± 2.2 98.30
120% PHE 18 17.70 ± 1.6 98.33
PAR 390 394.60 ± 1.5 101.17
CAF 30 30.6 ± 1.2 102.00
CET 6 6.05 ± 1.1 100.83
NIM 120 123.20 ± 2.2 102.66
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Y-intercept of the calibration curve. The recovery data for
accuracy studies are shown in Table 3.
3.2.5. System suitability parameters
System suitability tests are an integral part of the analytical
method it is used to verify adequacy of the resolution and
reproducibility of system. For study of system suitability
parameter, seven replicate injections of mixed standard
(100% level of labeled claim) solution were injected and
parameters such as peak area, retention time, asymmetry fac-
tor and theoretical plates of the peaks were calculated. The re-
sults are shown in Table 4.
3.2.6. Robustness studies
The robustness of a method is the ability to remain unaffected
by small changes in chromatographic parameters. Theexperimental conditions were purposely altered and the chro-
matographic resolution of PHE, PAR, CAF, CET and NIM
was assessed. The chromatographic parameters included vari-
ation of ﬂow rate second deliberate change was made by
change in pH and third was deliberate change in detection
wavelength. To study the effect of ﬂow rate on system suitabil-
ity parameters ±10% change on either side of actual ﬂow rate
was made i.e., from 1.0 to 1.1 mL/min and 0.9 mL/min, while
other conditions were held constant. For experiment to study
the effect of pH on system suitability parameters change in
pH of ±0.1 units on either side of actual pH of buffer was
made i.e., from 3.3 to 3.4 and 3.2 while other chromatographic
conditions were kept constant. For variation of detecting
wavelength change in detecting wavelength of ±5 nm was
made and system suitability parameters were recorded. All
the robustness studies were carried using a mix standard hav-
ing resultant concentration of 10 lg/ml for PHE, 325 lg/ml for
Table 4 System suitability data.
Std. Sol. Parameters (* mean values) n= 7± SD
RT*(min) Peak area Asymmetry* Theoretical plates*
PHE 1.8 ± 0.09 203999.3 ± 815.56 1.18 ± 0.02 657575 ± 3468.73
PAR 9.81 ± 0.12 5173470 ± 10541.9 1.6 ± 0.02 1531592 ± 20135.13
CAF 11.70 ± 0.01 986707 ± 4423.13 0.92 ± 0.01 315331 ± 4366.86
CET 14.17 ± 0.01 191474 ± 10481.3 1.02 ± 0.01 102295 ± 2213.37
NIM 16.35 ± 0.01 3986067 ± 4497.61 0.92 ± 0.005 584520 ± 2973.26
* Results are mean values (n= 7) ± SD
Figure 5 Chromatogram for marketed preparation.
Table 5 Results for assay of marketed formulation.
Commercial formulation Ingredients Labeled amount (mg) Amount found (mg) Found %
Ness cold plus PHE 15 14.95 99.67
PAR 325 328.30 101.01
CAF 25 25.80 103.20
CET 5 5.20 104.00
NIM 100 103.20 103.20
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NIM. The system suitability parameters considered for delib-
erate changes were %RSD of peak areas, mean tailing factor
and mean retention time.
3.2.7. Analysis of formulation
The developed method was successfully applied to analyze
PHE, PAR, CAF, CET and NIM in marketed tablet formula-
tion. The amounts recovered were expressed as a percentage of
the label claim. Analysis of marketed tablets Ness cold plus
(One Ness Pharmaceuticals Ltd) was carried out in developed
chromatographic conditions. No interferences of excipients
were observed in analysis, a representative chromatogram for
analysis of tablet formulation is shown in Fig 5. The mean per-
centage recovery of drug contents of tablets obtained by the
proposed method was noted. The percentage recovery found
was 99.67% for PHE, 101.01% for PAR, 103.20%, CAF
104% CET and 103.2% NIM. The results are given in Table 5.4. Conclusion
In this study, a validated simple and reliable HPLC–DAD pro-
cedure was described for the assay of a complex multi drug
combination consisting of PHE, PAR, CAF, CET and NIM
which is indicated for the treatment of allergic symptoms of
the nose or throat due to upper respiratory tract allergies asso-
ciated with headache. To our present knowledge, no attempts
have yet been made to assay this multidrug mixture by any
analytical methodology. All the ﬁve analytes (PHE, PAR,
CAF, CET and NIM) were successfully resolved and quanti-
ﬁed using a Reverse phase Phenomenex Kinetex-C18 column
in a relatively short run time with the last analyte eluting at
16.3 min the gradient program contributed total run time of
20 min. Reliability was guaranteed as validation experiments
proved that the HPLC method is linear in the proposed work-
ing range as well as accurate, precise and speciﬁc. The good
recovery percentage of tablet forms suggests that the excipients
598 A.P. Dewani et al.have no interference in the determination. The RSD (%) was
also less than 2 showing a high degree of precision of the meth-
od. The proposed method was also found to be robust with re-
spect to ﬂow rate, pH of mobile phase and detecting
wavelength hence it can be recommended for the routine qual-
ity control of the studied drugs, either in bulk form or in their
combination formulated in some other dosage form.Acknowledgments
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